311P PFS2 and 3 after first-line CDK4/6i in HR+/HER2- metastatic breast cancer patients based on PAM50 intrinsic subtype and treatment strategies within the SOLTI-1801 CDK-PREDICT studyP. Tolosa Ortega, E.M. Ciruelos, Isabel García-Fructuoso et al.|ESMO Open|2025Cited by 0
248P Real-world relapse-free survival in HR+/HER2- breast cancer with PAM50 intermediate-risk groupSantiago Terán, Rodrigo Sánchez-Bayona, M. Quevedo et al.|ESMO Open|2025Cited by 0
8P Genomic variants associated with interstitial lung disease in patients treated with trastuzumab-deruxtecan: Results from the PROCURE projectRodrigo Sánchez-Bayona, Cristina Rodríguez‐Antona, J. Cortés et al.|ESMO Open|2025Cited by 0